Vesti-PD: Visual Perturbation Training to Reduce Fall Risk in People With Parkinson's Disease

Sponsor
University Ghent (Other)
Overall Status
Recruiting
CT.gov ID
NCT05690308
Collaborator
(none)
50
1
2
21.4
2.3

Study Details

Study Description

Brief Summary

Falls during walking are common in people with Parkinson's Disease (PD). Fall risk can be attributed in part to the loss of automaticity in walking and an increased reliance on sensory cues, such as the input from the balance organ. In this project the investigators want to assess the effectiveness of rehabilitation training aiming to improve this vestibular input. The effects of a visual perturbation training in a virtual reality environment will be compared to conventional treadmill training.

Condition or Disease Intervention/Treatment Phase
  • Other: Visual perturbation treadmill training
  • Other: Regular treadmill training
N/A

Detailed Description

Fifty participants (50-65 years) with idiopathic PD (Hoehn & Yahr scale 2-3) will be randomly assigned to the intervention group receiving four weeks of VPT in a VR environment using the Gait Real-time Analysis Interactive Lab system (GRAIL) or a control group receiving four weeks of regular treadmill training. Primary outcome measures are spatio-temporal outcome parameters of gait and dynamic stability (gait speed, stride time/length, cadence, step-to-step variability, step width variability and trunk sway), and self-reported falls, and will be recorded at all testing phases (pre-test, after baseline, after intervention and after detraining). Secondary outcome measures will include assessments of central and peripheral vestibular function (Cervical and ocular Vestibular Evoked Myogenic Potentials) for correlation with the primary outcome measures. The secondary outcomes will be recorded at pre-testing and directly after the intervention phase.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Controlled TrialRandomized Controlled Trial
Masking:
Single (Participant)
Masking Description:
Participants will not be informed if they are allocated to the experimental intervention or the control 'sham' intervention.
Primary Purpose:
Treatment
Official Title:
A Novel Training Method to Reduce Fall Risk in People With Parkinson's Disease: The Role of the Balance Organ
Actual Study Start Date :
Dec 20, 2022
Anticipated Primary Completion Date :
Mar 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental visual perturbation treadmill training

Participants assigned to the experimental intervention will receive 6 weeks, 2x per week of visual perturbation treadmill training using the GRAIL system. This will consist of maximum 30 minutes of walking on the treadmill while translations and rotations of the projected environment are applied.

Other: Visual perturbation treadmill training
12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill in a virtual reality environment (Gait Real-time Analysis Interactive Lab system, MOTEK) with projected visual perturbations.

Sham Comparator: Control treadmill training

Participants assigned to the control intervention will receive 6 weeks, 2x per week of treadmill only training. This will consist of maximum 30 minutes of walking on the treadmill without any visual perturbations.

Other: Regular treadmill training
12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in gait speed after 6 weeks training [Week 1 to week 6 of training intervention]

    Delta in average gait speed in m/s

  2. Change from baseline in cadence after 6 weeks training [Week 1 to week 6 of training intervention]

    Delta in steps per minute

  3. Change from baseline in stride time after 6 weeks training [Week 1 to week 6 of training intervention]

    Delta in average duration (+variability) of a single step in ms

  4. Change from baseline in step length after 6 weeks training [Week 1 to week 6 of training intervention]

    Delta in average length (+variability) of a single step in cm

  5. Change from baseline in step width after 6 weeks training [Week 1 to week 6 of training intervention]

    Delta in average width(+variability) of a single step in cm

  6. Change from baseline in trunk sway after 6 weeks training [Week 1 to week 6 of training intervention]

    Delta in medio-lateral and anterior-posterior movement of the center of mass as determined using 3D motion capturing in cm

Secondary Outcome Measures

  1. Assessments of central and peripheral vestibular function [Pre-test 1 at start of the study]

    Cervical and ocular vestibular evoked myogenic potentials

  2. Assessments of central and peripheral vestibular function [Post-test within 1 week after conclusion of the training intervention]

    Cervical and ocular vestibular evoked myogenic potentials

  3. Self-reported falls [Monthly up to six months after last training]

    Falls recorded in fall diary

Other Outcome Measures

  1. Assessment of fear of falling [Pre-test 2 at start of the study]

    Fear of falling recorded using the Iconographical Falls Efficacy Scale

  2. Assessment of fear of falling [Post-test within 1 week after conclusion of the training intervention]

    Fear of falling recorded using the Iconographical Falls Efficacy Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Idiopathic Parkinson's disease

  • Aged between 50-65 years

  • Bilateral symptoms

  • Able to walk unassisted for 20 minutes (Hoehn & Yahr stage II-III)

  • Stable medication dosage (if any)

  • No cognitive disablity

Exclusion Criteria:
  • Non-idiopathic Parkinson's disease

  • Strong variation in expressed symptoms

  • Inability to walk unassisted for 20 minutes

  • Underwent a medical procedure to treat Parkinson symptoms (e.g. duodopa pump, deep brain stimulator)

  • Cognitive disability (score < 21 on the Montreal Cognitive Assessment)

  • Illness other than Parkinson's disease (flu, Covid-19) or disabilities that may affect gait or equilibrium

  • Clogged ear(s)

  • Regular fainting episodes

  • Weight over 120 kg

  • Participation in other clinical studies

Contacts and Locations

Locations

Site City State Country Postal Code
1 UZ Gent Ghent East-Flanders Belgium 9000

Sponsors and Collaborators

  • University Ghent

Investigators

  • Principal Investigator: Patrick Santens, Prof., UZ Gent

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Ghent
ClinicalTrials.gov Identifier:
NCT05690308
Other Study ID Numbers:
  • ONZ-2022-0404
First Posted:
Jan 19, 2023
Last Update Posted:
Jan 19, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Ghent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2023